Loading viewer...
investor_presentation
Format: PDF investor_presentation
© 2018 Tonix Pharmaceuticals Holding Corp. February 2018 – BIO CEO Version P0099 2-8-18 (Doc 0321) Investor Presentation
© 2018 Tonix Pharmaceuticals Holding Corp. February 2018 – BIO CEO
Version P0099 2-8-18 (Doc 0321)
Investor Presentation
© 2018 Tonix Pharmaceuticals Holding Corp. 2
Cautionary Note on Forward -Looking Statements
Certain statements in this presentation regarding strategic plans, expectations and objectives for future
operations or results are “forward -looking statements” as defined by the Private Securities Litigation Reform
Act of 1995. These statements may be identified by the use of forward -looking words such as “anticipate,”
“believe,” “forecast,” “estimate” and “intend,” among others . These forward -looking statements are based on
Tonix’s current expectations and actual results could differ materially . There are a number of factors that
could cause actual events to differ materially from those indicated by such forward -looking statements . These
factors include, but are not limited to, substantial competition ; our need for additional financing ; uncertainties
of patent protection and litigation ; uncertainties of government or third party payor reimbursement ; limited
research and development efforts and dependence upon third parties ; and risks related to failure to obtain
U.S. Food and Drug Administration clearances or approvals and noncompliance with its regulations . As with
any pharmaceutical under development, there are significant risks in the development, regulatory approval
and commercialization of new products . The forward -looking statements in this presentation are made as of
the date of this presentation, even if subsequently made available by Tonix on its website or otherwise . Tonix
does not undertake an obligation to update or revise any forward -looking statement, except as required by
law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended
December 31, 2016, as filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2017, and
periodic reports filed with the SEC on or after the date thereof . All of Tonix's forward -looking statements are
expressly qualified by all such risk factors and other cautionary statements .
© 2018 Tonix Pharmaceuticals Holding Corp. 3
Tonmya®1 (cyclobenzaprine HCl sublingual tablets) bedtime treatment for posttraumatric stress
•Phase 3 HONOR study in military -related PTSD enrolling
•Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)
TNX-102 SL (cyclobenzaprine HCl sublingual tablets) bedtime treatment for Agitation in Alzheimer’s
•Pre-IND meeting held Nov 2017
•IND to be submitted 1Q2018
Preview truncated — download the full document for the complete content.
investor_presentation
48 Pages
investor_presentation
21 Pages
Zebra Technologies
investor_presentation
Akerna